Pharma giant Novo Nordisk discloses breach of clinical trials data
Summary
Novo Nordisk, a major pharmaceutical company, has revealed a data breach impacting patient data from some of its clinical trials. The breach involved unauthorized access to sensitive information related to ongoing research.
IFF Assessment
FOE
This incident represents a data breach affecting sensitive patient information, which is detrimental to defenders aiming to protect health data.
Defender Context
This breach highlights the ongoing risks to sensitive patient data within the healthcare and pharmaceutical sectors. Defenders must be vigilant in securing clinical trial data, as it is a prime target for threat actors seeking valuable personally identifiable information (PII) and research insights.